SUMMARY OF THE RISK EVALUATION AND MITIGATION STRATEGIES (REMS) APPROVED BY THE FOOD AND DRUG ADMINISTRATION (FDA) SINCE THE START OF THEIR USE IN 2007

被引：0
|
作者：
Farmer, Brenna [1 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
来源：
CLINICAL TOXICOLOGY | 2011年 / 49卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
242
引用
收藏
页码：594 / 595
页数：2
相关论文
共 33 条
  • [1] THE IMPACT OF THE FDA'S RISK EVALUATION AND MITIGATION STRATEGIES (REMS) INITIATIVE ON PRESCRIPTION PATTERN FOR DRUGS APPROVED UNDER THE REMS PROGRAM AND RELEVANT NON-REMS COMPETITORS
    Horowicz-Mehler, N.
    Sepulveda, B.
    White, C.
    Doyle, J.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A203 - A203
  • [2] Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019
    Guadamuz, Jenny S.
    Qato, Dima M.
    Alexander, G. Caleb
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (03): : 299 - 301
  • [3] Assessment of the US food and drug administration's risk evaluation and mitigation strategy (REMS) for prasugrel (effient)
    Metkus, Thomas
    Curran, Jill
    Lin, Shanshan
    Qato, Dima M.
    Alexander, G. Caleb
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 299 - 299
  • [4] Analyzing the Effectiveness of the Food and Drug Administration Risk Evaluation and Mitigation Strategies Using the FDA Adverse Event Reporting System Database
    Chung, Stephanie
    Ohman-Strickland, Pamela
    Samet, Robin
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S204 - S204
  • [5] Impact of risk evaluation and mitigation strategies (REMS) on erythropoiesis stimulating agent use
    He, Mengdong
    Gagne, Joshua J.
    Kesselheim, Aaron S.
    Sarpatwari, Ameet
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 188 - 189
  • [6] Adverse event reporting to US Food and Drug Administration and risk evaluation and mitigation strategies
    Thompson, Deborah L.
    Welsh, Kerry
    Alimchandani, Meghna
    [J]. MOLECULAR THERAPY, 2023, 31 (04) : 918 - 918
  • [7] The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction
    Wu, Jasmanda
    Juhaeri, Juhaeri
    [J]. CLINICAL THERAPEUTICS, 2016, 38 (12) : 2526 - 2532
  • [8] FDA's Risk Evaluation and Mitigation Strategies (REMS): Effective and Efficient Safety Tools or Process Poltergeist?
    Wilson, Andrew
    Milne, Christopher-Paul
    [J]. FOOD AND DRUG LAW JOURNAL, 2011, 66 (04) : 569 - +
  • [9] The Food and Drug Administration Should Mandate Risk Evaluation and Mitigation Strategies Training for All Opioids
    Soelberg, Cobin D.
    Chou, Roger
    Ramachandran, Banu K.
    Berkeley, Abiona
    Brown, Raeford E.
    [J]. ANESTHESIA AND ANALGESIA, 2018, 126 (04): : 1413 - 1417
  • [10] The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?
    Cohen, Robert A.
    Brown, Robert S.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (05) : 604 - 606
1234